Amani Mental Health Services now incorporates GeneSight DNA testing as part of their Psychiatric Evaluation process.

About the GeneSight Test
GeneSight is a pharmacogenomic test that evaluates important genetic variations to predict how individuals might respond to certain medications. The results can indicate which medications may need dose adjustments, might be less effective, or could have a higher risk of side effects based on an individual’s genetic profile. The test is completely painless and non-invasive, as it involves a simple cheek swab—no needles are required.

Impact on Mental Health Medication
Incorporating GeneSight into psychiatric evaluations allows healthcare providers to make more informed decisions when prescribing mental health medications. By understanding how a patient’s unique genetic makeup interacts with different medications, clinicians can select treatments that are more likely to be effective, with fewer side effects. This personalized approach not only reduces the trial-and-error period often associated with finding the right medication but also significantly improves the overall success of mental health treatment.

GeneSight Psychotropic Clinical Studies
There are seven peer-reviewed studies validating the clinical and economic utility of the GeneSight Psychotropic test. Notably, in the GUIDED study, patients using GeneSight experienced a 50% relative improvement in remission rates compared to standard treatment.

Cost of the GeneSight Test
Many commercial and government insurance plans cover part or all of the GeneSight test cost. Patients with commercial insurance may also be eligible for the GeneSight Financial Assistance Program.